Pharmaceutical - Diabetes, GlaxoSmithKline


Current filters:


Popular Filters

FDA finally OKs GlaxoSmithKline’s Tanzeum to treat type 2 diabetes

FDA finally OKs GlaxoSmithKline’s Tanzeum to treat type 2 diabetes


UK pharma giant GlaxoSmithKline yesterday received the much anticipated approval from the US Food and…

albiglutideDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationTanzeumUSA

GSK announces delay in Mekinist/Tafinlar MAA; EU approval of Eperzan

GSK announces delay in Mekinist/Tafinlar MAA; EU approval of Eperzan


UK pharma giant GlaxoSmithKline released a couple of news items yesterday, one slightly negative regarding…


Positive EMA/CHMP opinion for GlaxoSmithKline’s diabetes drug Eperzan

Positive EMA/CHMP opinion for GlaxoSmithKline’s diabetes drug Eperzan


Among a batch of positive opinions issued today by the European Medicines Agency’ s Committee for Medicinal…


US FDA eases restrictions on GSK diabetes drug Avandia

US FDA eases restrictions on GSK diabetes drug Avandia


The US Food and Drug Administration yesterday (November 25) lifted some severe limitations on the prescribing…

AvandiaDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulation

Case study draws attention to innovator brand preferences in Kenya


Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

US PDUFA for GSK diabetes drug delayed


UK pharma giant GlaxoSmithKline (LSE: GSK) revealed on Friday (August 2) that the US Prescription Drug…

albiglutideDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulation

More ADA highlights, from Eli Lilly on dulaglutide, J&J on Invokana and GSK on albiglutide


Continued news from the 73rd Scientific Sessions of the American Diabetes Association being held in Chicago,…

albiglutideDiabetesdulaglutideEli LillyGlaxoSmithKlineInvokanaJohnson & JohnsonLY605541PharmaceuticalResearch

Majority vote from FDA advisory panel to ease restrictions on GSK's Avandia


A joint advisory committee to the US Food and Drug Administration (FDA) voted to continue to make UK…

AvandiaDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulation

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug


US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Anti-aging breakthrough could mean new drugs within five years


Drugs that combat aging may be available within five years, following landmark work led by an Australian…


Regulatory updates on GSK's albiglutide, Roche's hep C test, Activartis AV0113


UK pharma giant GlaxoSmithKline plc (LSE: GSK) says it has submitted a Marketing Authorization Application…

ActivartisalbiglutideAnti-viralsAV0113BiotechnologyDiabetesEperzanEuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRoche

Pfizer's Quillivant XR oral suspension now available in USA; GlaxoSmithKline files BLA for albiglutide


Confirming expectations announced when Pfizer (NYSE: PFE) revealed its $680 million acquisition of NextWave…

albiglutideDiabetesGlaxoSmithKlineMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticalQuillivantRegulation

News briefs on Sanofi, Novo Nordisk and GlaxoSmithKline/Amicus


Two US subsidiaries of French drug major Sanofi (Euronext: SAN) have agreed to pay $109 million to resolve…

Amicus TherapeuticsAmigalDiabetesFIAspFinancialGlaxoSmithKlineHyalganIDegLiraLegalNorth AmericaNovo NordiskPharmaceuticalRare diseasesResearchSanofi

Research shows diabetes drug rosiglitazone improves memory


Rosiglitazone, the active ingredient of GlaxoSmithKline's diabetes drug Avandia, has shown promise as…


GlaxoSmithKline readies for filing of diabetes drug albiglutide on positive final data


UK pharma giant GlaxoSmithKline (LSE: GSK) says that positive data from the Phase III Harmony 8 study…

albiglutideDiabetesGlaxoSmithKlineJanuviaMerck & CoPharmaceuticalRegulationResearch

Ph III albiglutide data in type 2 diabetes supports move to filing, says GSK


UK pharma giant GlaxoSmithKline plc (LSE: GSK) says that top-line results have been received from seven…

albiglutideDiabetesGlaxoSmithKlineHuman Genome SciencesPharmaceuticalResearch

GlaxoSmithKline’s albiglutide fails to show superiority over Novo Nordisk’s Victoza


UK pharma giant GlaxoSmithKline (LSE: GSK) released disappointing top-line results from the first of…

albiglutideDiabetesGlaxoSmithKlineNovo NordiskPharmaceuticalResearchVictoza

In India, Lilly and Boehringer link for diabetes drug marketing; GSK eyeing acquisitions


The Indian subsidiaries of US drug major Eli Lilly (NYSE: LLY) and independent German pharma company…

Asia-PacificBoehringer IngelheimDiabetesEli LillyGlaxoSmithKlineMarkets & MarketingMergers & AcquisitionsPharmaceutical

New twist in diabetes drugs could reduce life-threatening side effects


Researchers from Dana-Farber Cancer Institute in Boston and the Scripps Research Institute in Jupiter,…

ActosAvandiaDiabetesGlaxoSmithKlinePharmaceuticalResearchTakeda Pharmaceuticals

Back to top